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. Dose-dependent increase of PCNA monoubiquitination in H1299 cells. A) H1299 cells were treated with increasing concentrations of the indicated compounds (1, 5, and 25 µM) or a single concentration (25 µM) of 77 for 4 hr. Whole cell extracts were separated on 4-12% gradient SDS-PAGE and subjected to Western blotting with an antibody against PCNA. Figure S3 . Chemical stability of 70 measured as percent composition of molecule in aqueous solution at room temperature in A) DPBS pH 7.4 buffer; B) USP1/UAF1 HTS assay buffer at pH 7.8 (50 mM HEPES, 0.5 mM EDTA, 100 mM NaCl, 1 mM TCEP, 0.1 mg/mL BSA, and 0.01% Tween-20); C) USP1/UAF1 HTS assay buffer at pH 2 and D) at pH 9 buffer.
General Methods for Chemistry. All air or moisture sensitive reactions were performed under positive pressure of nitrogen with oven-dried glassware. Chemical reagents and anhydrous solvents were obtained from commercial sources and used as-is. Preparative purification was performed on a Waters semi-preparative HPLC. The column used was a Phenomenex Luna C18 (5 micron, 30 x 75 mm) at a flow rate of 45 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10% to 50% acetonitrile over 8 minutes was used during the purification. Fraction collection was triggered by UV detection (220 nm). Analytical analysis was performed on an Agilent 1200 LC-MS (Agilent Technologies). Method 1: A 3 minute gradient of 4% to 100% Acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8 minute run time at a flow rate of 1 mL/min. Method 2: A 7 minute gradient of 4% to 100% Acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with a 4.5 minute run time at a flow rate of 1 mL/min. A Phenomenex Luna C18 column (3 micron, 3 x 75 mm) was used at a temperature of 50 °C. All of the analogs for assay have purity greater than 95% based on both analytical methods. 1 H and 13 C NMR spectra were recorded on a Varian 400 (100) MHz spectrometer. High resolution mass spectrometry was recorded on Agilent 6210 Time-of-Flight LC-MS system. Figure S4 . Activity of compound 70 tested in duplicate against 80 different targets (GPCRs, ion channels and transporters). X-axis represents the mechanism of interest and Y-axis represents the % inhibition at 10 µM. Compound binding was calculated as a % inhibition of the binding of a radioactively labeled ligand specific for each target. 0.55 mmol) in DME (1 mL) was sealed in a microwave vial and heated in a Biotage Initiator microwave reactor to 150 ºC for 10 min.
The reaction was cooled, filtered over celite, concentrated, and purified via reversed phase HPLC to give the desired product. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.02 − 9.12 (m, 1 H), 1 H), 1 H), 3 H), 7 H), 7.52 (d, J = 8.22 Hz, 3 H), and 4.97 (d, J = 5.48 Hz, 2 H); LC-MS retention time (Method 1): 2.502 min; (Method 2): 5.389 min; HRMS: m/z (M+H) + = (Calculated for C 28 H 19 F 6 N 4 525.1508) found, 525.1522.
N-(4-cyclohexylbenzyl)-2-(2-(trifluoromethyl)phenyl)quinazolin-4-amine TFA (21):
Follow the synthesis for compound 2, (Method A) but substitute (4-cyclohexylphenyl)methanamine for (5-methylthiophen-2-yl)methanamine: 1 
Method B:
(a) (4-(pyridin-3-yl)phenyl)methanamine, Et 3 N (3.0 equiv), CHCl 3 , 18 h, 60 o C (b) RB(OH) 2 (3.0 equiv), 2M Na 2 CO 4 (4.0 equiv), DPP-Pd silica bound (0.3 equiv), or Pd(PPh 3 ) 4 (0.2 equiv), DME, MW, 150 o C, 45 min (c) amine (1.2 equiv) , THF, reflux. 18 h.
2-Chloro-N-(4-(6-methylpyridin-3-yl)benzyl)quinazolin-4-amine (iv):
2,4-Dichloroquinazoline (70 mg, 0.35 mmol) (iii), (4-(6-methylpyridin-3-yl)phenyl)methanamine (77 mg, 0.39 mmol), Et 3 N (0.15 mL, 1.06 mmol), in CHCl 3 (2 mL), was heated in a sealed tube for 3 h at 50 o C. The resulting mixture was cooled and placed on a silica column for purification with EtOAc/Hex 0 to 100% gradient over 20 min, to give the desired product in a 70% yield. LC-MS retention time (Method 1): 2.760 min; S13 N-(4-(pyridin-3-yl)benzyl)-2-(3-(trifluoromethyl)phenyl)quinazolin-4-amine TFA (22): 2-Chloro-N-(4-(6-methylpyridin-3-yl)benzyl)quinazolin-4-amine (iv) (107 mg, 0.31 mmol), 3trifluoromethylphenyl boronic acid (56 mg, 0.37 mmol), Pd(PPh 3 ) 4 (36.0 mg, 0.03 mmol), 2 M solution of Na 2 CO 3 (0.30 mL, 0.62 mmol) in DME (1 mL) was sealed in a microwave vial and heated in a Biotage Initiator microwave reactor to 150 ºC for 30 min. The reaction was cooled, filtered over celite, concentrated, and purified to give the desired product. 1 
N-(4-(pyridin-3-yl)benzyl)-2-(4-(trifluoromethyl)phenyl)quinazolin-4-amine TFA (23):
Follow the procedure for compound 22, (Method B) but substitute 4trifluoromethylphenylboronic acid for 3-trifluoromethylphenylboronic acid: 1 
2-(2-nitrophenyl)-N-(4-(pyridin-3-yl)benzyl)quinazolin-4-amine TFA (24):
Follow the procedure for compound 22, (Method B) but substitute 2-nitrophenylboronic acid for 3trifluoromethylphenylboronic acid: 1 
N-(4-(pyridin-3-yl)benzyl)-2-o-tolylquinazolin-4-amine TFA (26):
Follow the procedure for compound 22, (Method B) but substitute 2-methylphenylboronic acid for 3trifluoromethylphenylboronic acid: 1 
2-cyclopentyl-N-(4-(pyridin-3-yl)benzyl)quinazolin-4-amine (33):
Follow the procedure for compound 2, (Method A) but substitute cyclopentanecarbonyl chloride for 2-(trifluoromethyl)benzoic acid, and substitute (4-(pyrimidin-5-yl)phenyl)methanamine for thiophen-2-ylmethanamine: 1 
2-morpholino-N-(4-(pyridin-3-yl)benzyl)quinazolin-4-amine TFA (34):
Follow the procedure for the synthesis of 2-chloro-N-(4-(6-methylpyridin-3-yl)benzyl)quinazolin-4-amine (iv) Method B.
Step c 2-Chloro-N-(4-(6-methylpyridin-3-yl)benzyl)quinazolin-4-amine (50 mg, 0.14 mmol), mopholine (15 µL, 0.17 mmol), in THF (1 mL), was heated in a sealed tube to reflux for 24 h. The mixture was cooled, concentrated, and purified to give the desired product. 1 
N-(4-(pyridin-3-yl)benzyl)-2-(pyrrolidin-1-yl)quinazolin-4-amine

2-(1H-imidazol-1-yl)-N-(4-(pyridin-3-yl)benzyl)quinazolin-4-amine (36):
Follow the procedure for compound 34 (Method B) but substitute 1H-imidazole for mopholine: 1 
Method C:
(a) (4-(pyridin-3-yl)phenyl)methanamine, NEt 3 , CHCl 3 , 18 h, 60 o C (f) 2-isopropylphenyl boronic acid (3.0 equiv), 2M Na 2 CO 4 (4 equiv), DPP-Pd silica bound (0.3 equiv), DME, MW, 150 o C, 45 min.
2-Chloro-5-methyl-N-(4-(pyridin-3-yl)benzyl)pyrimidin-4-amine TFA (vi):
(4-(pyridin-3yl)phenyl)methanamine (0.37 mmol), 2,4-dichloropyrimidine (v) (0.41 mmol), and triethylamine (1.10 mmol), were heated overnight to 60 ºC in CHCl 3 (1 mL). Once completed the reaction was poured into water and extracted with dichloromethane. The organic layer was washed with water (1X), saturated sodium bicarbonate (1X), dried over Na 2 SO 4 , filtered, concentrated, and purified on a prep-HPLC system (gradient 10-100% acetonitrile w/ 0.1% TFA in water w/ 0.1% TFA) to give the desired product: LC-MS retention time (Method 1): 2.617 min. This intermediate was used without further characterization.
General Method C for Suzuki coupling:
In a sealed tube containing 2-chloro-N-(4-(pyridin-3yl)benzyl)pyrimidin-4-amine (vi) (0.32 mmol) was added 2-isopropylphenylboronic acid (0.39 mmol), sodium carbonate (2.0 M in water, 0.64 mmol), and Pd(PPh 3 ) 4 (0.03 mmol) in DME (2 mL), and heated at 150 ºC for 30-45 min in a Biotage Initiator microwave reactor. The resulting mixture was filtered over celite and purified via reversed phase HPLC (unless otherwise stated) to give the desired products: 
5-Fluoro-2-(2-isopropylphenyl)-N-(4-(pyridin-3-yl)benzyl)pyrimidin-4-amine (50): Follow
General Method C using 2,4-dichloro-5-fluoropyrimidine for the core: 1 
2-(2-Isopropylphenyl)-N-4-(4-(pyridin-3-yl)benzyl)pyrimidine-4,5-diamine TFA (51):
Follow General Method C using 5-amino-2,4-dichloropyrimidine for the core: 1 
2-(2-Isopropylphenyl)-5-(methylthio)-N-(4-(pyridin-3-yl)benzyl)pyrimidin-4-amine TFA (53):
Follow General Method C using 2,4-dichloro-5-(methylthio)pyrimidine for the core. Synthesis of 2,4-dichloro-5-(methylthio)pyrimidine was achieved by combining 5bromopyrimidine-2,4(1H,3H)-dione (0.50 g, 2.62 mmol), sodium thiomethoxide (0.33 g, 4.71 mmol) and DMSO (5 mL) in a 10-20 mL microwave vial. The vial was sealed and heated to 100 ºC for 30 min in a Biotage Initiator microwave reactor, cooled to rt, poured into water and extracted with EtOAc (2X). The organic layers were combined and washed with water (3X), dried over Na 2 SO 4 , filtered, concentrate and purified on prep HPLC (gradient 10-100% acetonitrile w/ 0.1% TFA in water w/ 0.1% TFA). 5-(methylthio)pyrimidine-2,4(1H,3H)-dione TFA (0.50 g, 0.32 mmol), N,N-dimethylaniline (0.40 mL, 3.16 mmol), and POCl 3 (1.00 mL, 10.73 mmol) were refluxed for 5 h, cooled to rt, poured into a cold solution of sodium bicarbonate, extracted with EtOAc (1X), dried with Na 2 SO 4 , filtered, concentrated, and used without further purification. 1 Step a 2,4-dichloro-5-methylpyrimidine (0.35 mmol) (vii), (R)methanamine (0.39 mmol), Et 3 N (1.06 mmol), in CHCl 3 (2 mL), was heated in a sealed tube for 18 h to 100 o C. The resulting mixture was cooled and placed on a silica column for purification with EtOAc/Hex 0 to 100% gradient over 20 min.
Step b: In a sealed tube 2-chloro-N-(R)-5-methylpyrimidin-4-amine viii (0.32 mmol) was combined with (2-isopropylphenyl)boronic acid (0.39 mmol), sodium carbonate (2.0 M in water, 0.64 mmol), and DPP-Pd silica bound Silicycle (0.26 mmol/g, 19 mol %) in DME (2.00 mL), and heated at 150 ºC for 30 min in a Biotage Initiator microwave reactor. The resulting mixture was filtered over celite and purified to give the desired products: N-(pyridin-3-ylmethyl) = (Calculated for C 20 H 24 N 4 319.1917 = (Calculated for C 20 H 24 N 4 319. found, 19.1921 . N-((1-methylpiperidin-4-yl) 
2-(2-Isopropylphenyl)-5-methyl-N-(3-methylbenzyl)pyrimidin-4-amine TFA (54): Follow
2-(2-Isopropylphenyl)-5-methyl-
(4-(2-(R)-pyridin-4-yl)phenyl)methanamine (x) :
(4-bromophenyl)methanamine (ix) (1.08 mmol), (R)-(pyridin-4-yl)boronic acid (1.40 mmol), Na 2 CO 3 solution in water (2 M, 2.15 mmol), DPP-Pd silica bound Silicycle (0.26 mol/g, 19 mol %) in DME (4 mL) was sealed in a microwave vial and heated in a Biotage Initiator microwave reactor to 150 ºC for 10 min. The reaction was filtered over celite, concentrated, and purified on silica gel 0-5% gradient MeOH/DCM with 1% ammonia to give the desired product. N-((2-(R)-methyl) pyridin-4-yl)benzyl)pyrimidin-4-amine TFA (Step b): 2,4-dichloro-5-methylpyrimidine (0.40 mmol), (4-((R)-methyl)pyridin-4-yl)phenyl)methanamine (0.48 mmol), Et 3 N (1.2 mmol), in DMF was heated to 100 ºC for 18 h. The reaction was poured into water and extracted with EtOAc (1X). The organic layer were washed with water (3 X), dried over Na 2 SO 4 , filtered, concentrated, and purified on a prep-HPLC (gradient 10-100% acetonitrile w/ 0.1% TFA in water w/ 0.1% TFA) to give the desired product. (4-(6-fluoropyridin-3-yl)benzyl)-2-(2-isopropylphenyl) -(2-Isopropylphenyl)-5-methyl-N-(4-(6-methylpyridin-3-yl) F   2-(2-Isopropylphenyl)-5-methyl-N-(piperidin-4-ylmethyl) pyrimidin-4-amine TFA (xi): 2,4-Dichloro-5-methylpyrimidine (vii) (0.20 g, 1.23 mmol), tert-butyl 4-(aminomethyl)piperidine-1carboxylate (62-65), tert-butyl 3-(aminomethyl)azetidine-1-carboxylate (66), or tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate (67), (1.47 mmol), Et 3 N (0.51 mL, 3.86), CHCl 3 (3 mL), was heated to 60 o C for 18 h. The reaction mixture was cooled to rt, poured into NaHCO 3 and washed (2 X), dried over Na 2 SO 4 , concentrated and purified on silica gel DCM/MeOH. Tertbutyl 4-((2-chloro-5-methylpyrimidin-4-ylamino)methyl)piperidine-1-carboxylate (0.25 g, 0.72 mmol), 2-isopropylphenylboronic acid (0.14 g, 0.86 mmol), Pd(PPh 3 ) 4 , (0.08 g, 0.07 mmol), Na 2 CO 3 (2 M, 0.72 mL, 1.44 mmol) in DME (2 mL), was sealed in a microwave vial and heated to 150 o C for 30 min. The mixture was cooled to rt and filtered through celite, concentrated and purified on reverse phase with MeCN/H 2 O with 0.1% TFA gradient 10 to 100 % over 20 min. This compound was used as is with no further characterization. Follow General Method D for the Suzuki coupling. (4-(1H-1,2,3-triazol-1-yl)benzyl)-2-(2-tert-butylphenyl) -5-methylpyrimidin-4-amine TFA (62): Method F step c: 2-(2-isopropylphenyl)-5-methyl-N-(piperidin-4-ylmethyl)pyrimidin-4amine (0.13 g, 0.39 mmol), NaBH(AcO) 3 (0.82 g, 3.85 mmol), and oxetan-3-one (0.02 mL, 0.39 mmol), were stirred in DCE (2 ml) for 2 h. When complete the reaction mixture was poured into saturated solution of sodium bicarbonate and extracted with DCM, dried over Na 2 SO 4 , filtered, concentrated, and purified to give the desired product: 1 N-((1-(pyrazin-2-yl) N-(4-(1H-imidazol-1-yl)benzyl)-2-(2-isopropylphenyl) -5-methylpyrimidin-4-amine (69): Follow General Method D and use (4-(1H-imidazol-1-yl)phenyl)methanamine. which was synthesized by heating 1-(4-(chloromethyl)phenyl)-1H-imidazole (0.50g, 2.6 mmol), and potassium phthalimide (0.58 g, 3.1 mmol) in DMF (2.5 mL) at 120 o C for 18 h. The reaction mixture was cooled to 0 o C, poured into water, the solids were filtered, and washed with water to give 2-(4-(1H-imidazol-1-yl)benzyl)isoindoline-1,3-dione. The dried 2-(4-(1H-imidazol-1yl)benzyl)isoindoline-1,3-dione (0.40g, 1.32 mmol) was heated to 95 o C in a mixture of EtOH and hydrazine (4:1) for 1 h, cooled and the solids filtered and washed with EtOH to give (4-(1Himidazol-1-yl)phenyl)methanamine in an 88% yield. This material was used in the synthesis of N-(4-(1H-imidazol-1-yl)benzyl)-2-chloro-5-methylpyrimidin-4-amine. 1 Hz, 1 H), 3 H), 5 H), 7.33 (ddd, J = 1.44, 6.97, and 7.67 Hz, 1 H), 4.81 (d, J = 5.97 Hz, 2 H), 3.10 (td, J = 7.44, 13.64, and 14.23 General Method G: (steps a-c) are reported in the main text. 1H-1,2,3-triazol-1-yl) TFA (xiii, 1b) : 4-(1H-1,2,3-triazol-1yl)benzonitrile (0.45 g, 2.64 mmol), in THF (2.40 mL), was cooled to 0 ºC, treated by dropwise addition of lithium aluminum deuteride (7.93 ml, 7.93 mmol) once the addition was completed the reaction was allowed to warm to rt, and stirred for 1.5 h. The reaction was quenched by treating with 3 mL of 1 N NaOH and 2 mL of water at 0 ºC. A white solid was filtered after 20 min and washed with THF, followed by ethyl acetate. The filtrate was concentrated to an orange/brown residue and purify by prep-HPLC system (gradient 10-100% acetonitrile w/ 0.1% TFA in water w/ 0.1% TFA) to give the desired product in a 40% yield: 1 N-(4-(1H-1,2,3-triazol-1-yl) 
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benzyl)-2-chloro-5-methylpyrimidin-4-amine TFA (xiv):
(4-(1H-1,2,3-triazol-1-yl)phenyl)methanamine, TFA (1a or 1b) (0.52 g, 1.88 mmol), 2,4-dichloro-5methylpyrimidine (0.29 g, 1.88 mmol), and triethylamine (1.00 mL, 7.20 mmol), in DMF (7 mL) was heated overnight to 100 ºC. Once completed the reaction was poured into water (30 mL) and extracted with ethyl acetate and seperated. The ethyl acetate layer was wash with water (2 X), saturated sodium bicarbonate, dried over Na 2 SO 4 , filtered, concentrated, and purified by prep HPLC (gradient 10-100% acetonitrile w/ 0.1% TFA in water w/ 0.1% TFA) to give 0.19 g of desired product: LC-MS retention time (Method 1): 2.770 min.
2-(2-Cyclopropylphenyl)-5-methyl-N-(4-(pyridin-3-yl)benzyl)pyrimidin-4-amine) TFA (71):
Follow General Method C using (2-cyclopropylphenyl)boronic acid for (2isopropylphenyl)boronic acid which was synthesized using 2-(2-chlorophenyl)-5-methyl-N-(4-(pyridin-3-yl)benzyl)pyrimidin-4-amine (0.05 g, 0.13 mmol), (2-cyclopropyl)boronic acid (0.01 g, 0.16 mmol), K 3 PO 4 (0.08 g, 0.39 mmol) and tricyclohexylphosphine (0.02 mL, 0.01 mmol) in toluene (2 mL) and water (0.10 mL). The mixture was placed under nitrogen and PdOAc 2 (1.45 mg, 6.46 µmol), was added and heated to 150 °C for 30 min. The reaction was allowed to cool to rt, then filtered and purified to give the desired product: 1 
5-methyl-2-(2-(oxetan-3-yl)phenyl)-N-(4-(pyridin-3-yl)benzyl)pyrimidin-4-amine TFA (72):
Follow Method C for viii: The synthesis for compound xv 3-(2-bromophenyl)oxetane was achieved using the method described by Jacobsen et. al, except diethyl 2-(2bromophenyl)malonate was used as the starting material instead of diethyl 2-(2-(benzyloxy)phenyl)malonate. This synthetic sequence was carried on without further purification/characterization of the intermediates. In an oven-dried 50 mL round bottom flask, 3-(2-bromophenyl)oxetane xv (0.14 g, 0.66 mmol) and THF (4 mL) was cooled to -78 ºC. The dropwise addition of N-butyllithium (0.85 mL, 1.36 mmol), by syringe occurred over a 15 min period. After this time, the reaction mixture was allowed to stir at -78 ºC for an additional 2 h and contents transferred via cannula to a second 50 mL oven-dried round bottom flask containing a stirred solution of triisopropyl borate (0.29 mL, 1.32 mmol), and THF (2.0 mL) cooled to -78 ºC. Once transferred, the mixture was allowed to stir at -78 ºC for 10 min after which time the ice bath was removed and the reaction mixture stirred overnight. 1 N HCl was 
1-(2-bromophenyl)ethanone (d 3 ) (a):
1-(2-bromophenyl)ethanone (xix) (1.00 ml, 7.44 mmol), D 2 O (13.46 ml, 744 mmol), and 4Å molecular sieves (~10 beads) were combined in a 10-20 mL microwave vial, which was sealed and heated to 180 ºC for 30 min. The biphasic mixture was S39 allow to cool to rt, poured into water, extracted with ether (3 X), dried over MgSO 4 and concentrated to give 1.3 g as clear glasslike oil. The compound was used as-is in the next reaction: 1 H NMR (400 MHz, Chloroform-d) δ 7.59 (ddt, J = 1.3, 2.6, and 8.0 Hz, 1 H), 7.46 (dd, J = 1.6, and 7.9 Hz, 1 H), 7.35 (m, 1 H), and 7.28 (tq, J = 1.7, and 7.7 Hz, 1 H); 13 C NMR (101 MHz, CDCl 3 ) δ 201. 24, 149.22, 141.30, 134.27, 133.27, 131.84, 128.32, and 29.13 ; LC-MS retention time (Method 1): 3.337 min. (2-Bromophenyl) propan-2-ol (d 6 ) (b): 2-bromo-acetophenone (d 3 ) (1.0 g, 14.9 mmol) and diethyl ether (148 mL) were chilled to -8 ºC. 1 M methyl (d 3 ) magnesium iodide in diethyl ether (20.0 mL, 20.0 mmol) was added by syringe over a 45 min keeping the temperature at -8 ºC.
2-
The milky white solution which was allowed to stir for 2 h at -8 ºC, was poured into ice with saturated NH 4 Cl and extract with ether (3X). The organic layers were combined, dried over MgSO 4 , filtered, concentrated, and purified withEtOAc/Hex 0-20% gradient to give 2.5 g of a clear glasslike oil in a 76% yield: 1 04, 135.07, 128.50, 127.52, 127.26, 127.19, 120.45, 73.26, and 28 .56: LC-MS retention time (Method 1): 3.749 min.
1-Bromo-2-isopropyl(d 7 )benzene (xx): 2-(2-bromophenyl)propan-2-ol (d 6 ) (0.63 g, 2.87 mmol), trimethylsilane(d) (0.70 mL, 4.30 mmol), TFA(d) (2.20 mL, 28.70 mmol) was stirred in anhydrous DCM (4.5 ml) and followed by TLC (80/20 hexanes/EtOAc, with p-anisaldehyde (PAA) stain) for 45 min. The reaction mixture was concentrated, and purified with 0-20% EtOAc/Hex to give the desired product as a clear glasslike oil in a 73% yield: LC-MS retention time (Method 1): 3.941 min. (For the d 6 compound used trimethylsilane and TFA).
(2-isopropyl(d 7 )phenyl)boronic acid (xxi): In an oven dried 100 mL round bottom flask 1bromo-2-isopropyl(d 7 )benzene (0.70 g, 3.40 mmol) and THF (14 mL) were cooled to -78 ºC. The dropwise addition of N-butyllithium (4.25 mL, 6.80 mmol), by syringe, occurred over a 15 min period and the reaction continued to stir at -78 ºC for 2 h. The contents were transferred by cannula to a second 100 mL oven dried round bottom flask containing a stirred solution of triisopropyl borate (1.50 mL, 6.79 mmol), and THF (7.0 mL) at -78 ºC. Once transferred, the mixture was allowed to stir at -78 ºC for 10 min at which time the ice bath was removed and the reaction stirred overnight. 1N HCl was used to adjust the pH to 1, and the acidic mixture was stirred for 45 min, poured into water, and extracted with diethyl ether (3 X). The organic layers were combined, dried over MgSO4, concentrated, and once the solvent was removed by evaporation, a 1 M solution of 3.40 mmol in 1,2-DME was made and used in next step with no further purification or characterization.
